JP2023519173A5 - - Google Patents

Info

Publication number
JP2023519173A5
JP2023519173A5 JP2022554368A JP2022554368A JP2023519173A5 JP 2023519173 A5 JP2023519173 A5 JP 2023519173A5 JP 2022554368 A JP2022554368 A JP 2022554368A JP 2022554368 A JP2022554368 A JP 2022554368A JP 2023519173 A5 JP2023519173 A5 JP 2023519173A5
Authority
JP
Japan
Prior art keywords
protein
nucleic acid
acid molecule
cancer
polynucleotide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022554368A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023519173A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/021573 external-priority patent/WO2021183564A1/en
Publication of JP2023519173A publication Critical patent/JP2023519173A/ja
Publication of JP2023519173A5 publication Critical patent/JP2023519173A5/ja
Pending legal-status Critical Current

Links

JP2022554368A 2020-03-09 2021-03-09 免疫応答を誘導するための組成物及び方法 Pending JP2023519173A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202062987191P 2020-03-09 2020-03-09
US62/987,191 2020-03-09
US202063073900P 2020-09-02 2020-09-02
US63/073,900 2020-09-02
PCT/US2021/021573 WO2021183564A1 (en) 2020-03-09 2021-03-09 Compositions and methods for inducing immune responses

Publications (2)

Publication Number Publication Date
JP2023519173A JP2023519173A (ja) 2023-05-10
JP2023519173A5 true JP2023519173A5 (cg-RX-API-DMAC7.html) 2024-03-19

Family

ID=77671984

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022554681A Pending JP2023517644A (ja) 2020-03-09 2021-03-09 コロナウイルスワクチン組成物及び方法
JP2022554368A Pending JP2023519173A (ja) 2020-03-09 2021-03-09 免疫応答を誘導するための組成物及び方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2022554681A Pending JP2023517644A (ja) 2020-03-09 2021-03-09 コロナウイルスワクチン組成物及び方法

Country Status (7)

Country Link
US (6) US11759515B2 (cg-RX-API-DMAC7.html)
EP (2) EP4117725A4 (cg-RX-API-DMAC7.html)
JP (2) JP2023517644A (cg-RX-API-DMAC7.html)
AU (2) AU2021236068A1 (cg-RX-API-DMAC7.html)
CA (2) CA3171219A1 (cg-RX-API-DMAC7.html)
TW (2) TW202613312A (cg-RX-API-DMAC7.html)
WO (2) WO2021183564A1 (cg-RX-API-DMAC7.html)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10526284B2 (en) * 2016-12-21 2020-01-07 Arcturus Therapeutics, Inc. Ionizable cationic lipid for RNA delivery
US10383952B2 (en) 2016-12-21 2019-08-20 Arcturus Therapeutics, Inc. Ionizable cationic lipid for RNA delivery
US11679163B2 (en) 2019-09-20 2023-06-20 Hdt Bio Corp. Compositions and methods for delivery of RNA
WO2021194672A1 (en) 2020-03-23 2021-09-30 Hdt Bio Corp. Compositions and methods for delivery of rna
JP2023517644A (ja) 2020-03-09 2023-04-26 アークトゥラス・セラピューティクス・インコーポレイテッド コロナウイルスワクチン組成物及び方法
US12558415B2 (en) * 2020-04-14 2026-02-24 The Regents Of The University Of California Broad-spectrum multi-antigen pan-coronavirus vaccine
CN118490818A (zh) 2020-04-22 2024-08-16 生物技术欧洲股份公司 冠状病毒疫苗
WO2022011332A2 (en) * 2020-07-10 2022-01-13 Engimata, Inc Immunogenic composition forming a vaccine, and a method for its manufacture
US12178921B2 (en) 2020-08-14 2024-12-31 Arcturus Therapeutics, Inc. Method of lyophilizing lipid nanoparticles
SE544840C2 (en) * 2020-09-28 2022-12-13 Stora Enso Oyj Method for the preparation of a bio-based carbon foam
MX2023004371A (es) 2020-10-14 2023-07-26 George Mason Res Foundation Inc Lípidos ionizables, y métodos de fabricación y uso de los mismos.
TW202237148A (zh) * 2020-11-16 2022-10-01 德商拜恩迪克公司 包含rna之lnp組合物以及製備、儲存及使用彼之方法
CN117098541A (zh) 2020-11-25 2023-11-21 阿卡格拉医药公司 用于递送核酸的脂质纳米粒及相关使用方法
US20220356212A1 (en) * 2021-03-26 2022-11-10 Nanogen Pharmaceutical Biotechnology JSC Modified spike protein and method of treatment
EP4376883A4 (en) * 2021-07-30 2025-07-16 Arcturus Therapeutics Inc RNA VACCINES
EP4763287A2 (en) 2021-09-03 2026-06-24 CureVac SE Novel lipid nanoparticles for delivery of nucleic acids
AU2022347195A1 (en) * 2021-09-20 2024-05-02 Cyanvac Llc Piv5-based coronavirus vaccines and methods of use thereof
JP2024535352A (ja) 2021-09-22 2024-09-30 エイチディーティー バイオ コーポレーション Sars-cov-2 rnaワクチン組成物および使用方法
CA3232658A1 (en) 2021-09-22 2023-03-30 Steven Gregory REED Rna vaccines against infectious diseases
WO2023049636A2 (en) 2021-09-22 2023-03-30 Hdt Bio Corp. Cancer therapy compositions and uses thereof
AU2022352486A1 (en) 2021-09-22 2024-04-11 Hdt Bio Corp. Dried nanoparticle compositions
EP4413144A4 (en) * 2021-10-07 2025-11-19 Global Life Sciences Solutions Canada Ulc RNA VACCINE LIPID NANOPARTICLES
WO2023079472A2 (en) * 2021-11-03 2023-05-11 Kashiv Biosciences, Llc Multicistron expression vector for covid-19 vaccine
US20230159449A1 (en) * 2021-11-03 2023-05-25 Arcturus Therapeutics, Inc. Lipid formulations containing nucleic acids and methods of treatment for cystic fibrosis
US11510975B1 (en) * 2021-11-29 2022-11-29 Replicate Bioscience, Inc. Compositions and methods for inducing ESR1, PI3K, HER2, and HER3 immune responses
CA3238159A1 (en) * 2021-11-29 2023-06-01 Hong Jiang Sars cov-2 vaccine, associated polynucleotides, and methods of use
US12186387B2 (en) 2021-11-29 2025-01-07 BioNTech SE Coronavirus vaccine
US20250041238A1 (en) * 2021-12-23 2025-02-06 Etherna Immunotherapies Nv METHOD FOR LAGRE-SCALE PRODUCTION OF LARGE-SIZE LNPs
EP4460509A1 (en) * 2022-01-05 2024-11-13 Helix Nanotechnologies Inc Compositions comprising alpha-factor prepro sequence and uses thereof
EP4469091A1 (en) 2022-01-28 2024-12-04 CureVac SE Nucleic acid encoded transcription factor inhibitors
JP2025507234A (ja) * 2022-02-07 2025-03-18 セキラス・インコーポレイテッド 自己複製rna及びその使用配列表 本出願は、電子形態の配列表とともに出願される。配列表の全内容は、参照によって本明細書に組み込まれる。
CN116768987A (zh) * 2022-03-09 2023-09-19 中生复诺健生物科技(上海)有限公司 编码新型冠状病毒S蛋白的mRNA疫苗
EP4511497A4 (en) * 2022-04-19 2026-04-22 Replicate Bioscience Inc MODIFIED WESTERN EQUINE ENCEPHALITIS VIRUS AND ITS USES
CN114557971B (zh) * 2022-04-25 2023-05-23 康希诺生物股份公司 一种核酸-脂质纳米颗粒的冷冻干燥保护剂及其制备方法和应用
EP4522754A1 (en) * 2022-05-12 2025-03-19 Sunvax MRNA Therapeutics Inc. Synthetic self-amplifying mrna molecules with secretion antigen and immunomodulator
WO2023221938A1 (zh) * 2022-05-16 2023-11-23 上海行深生物科技有限公司 蛋白包裹自复制rna及其制备方法
CA3248209A1 (en) 2022-05-25 2023-11-30 CureVac SE Escherichia coli Antigenic Polypeptide-Based Nucleic Acid Vaccine (FIMH)
WO2023230587A2 (en) * 2022-05-25 2023-11-30 Akagera Medicines, Inc. Lipid nanoparticles for delivery of nucleic acids and methods of use thereof
US11878055B1 (en) 2022-06-26 2024-01-23 BioNTech SE Coronavirus vaccine
US20240100152A1 (en) * 2022-09-06 2024-03-28 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Modified polynucleotides encoding the sars-cov-2 spike protein for safer designs of coronavirus vaccines
WO2024089229A1 (en) * 2022-10-28 2024-05-02 CureVac SE Improved formulations comprising lipid-based carriers encapsulating rna
US12186388B2 (en) * 2022-11-02 2025-01-07 Centre For Virology, Vaccinology And Therapeutics Limited Interferon-producing universal sarbecovirus vaccines, and uses thereof
TW202438672A (zh) * 2023-01-31 2024-10-01 美商亞克圖羅斯醫療公司 四價流感疫苗之方法及組成物
KR20250153298A (ko) 2023-03-08 2025-10-24 큐어백 에스이 핵산 전달을 위한 신규의 지질 나노입자 제형
WO2024230934A1 (en) 2023-05-11 2024-11-14 CureVac SE Therapeutic nucleic acid for the treatment of ophthalmic diseases
EP4719352A1 (en) 2023-05-31 2026-04-08 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
AU2024381228A1 (en) * 2023-11-13 2026-05-28 Ziphius Nv MODIFIED ALPHAVIRAL nsP3
WO2025103803A1 (en) 2023-11-13 2025-05-22 CureVac SE Immunotherapy against neuronal and brain tumors
WO2025103414A1 (zh) * 2023-11-14 2025-05-22 上海瑞宏迪医药有限公司 一种脂质纳米粒的制备方法和应用
GB202400648D0 (en) * 2024-01-17 2024-02-28 Uea Enterprises Ltd Protein replacement therapy
WO2025189168A1 (en) * 2024-03-08 2025-09-12 SunVax mRNA Therapeutics Inc. Methods for cascade amplifications of therapeutic payloads (catp) & compositions for cancer immunotherapies and gene therapy
US20260002196A1 (en) * 2024-07-01 2026-01-01 New England Biolabs, Inc. Programmable Cleavage of RNA
WO2026041140A1 (zh) * 2024-08-23 2026-02-26 康希诺(上海)生物研发有限公司 一种自复制rna分子及其制备方法和应用
JP7657411B1 (ja) * 2025-01-23 2025-04-07 医療法人すぎやま内科 乳がん細胞の増殖抑制剤及び乳がん治療剤

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003023026A1 (en) 2001-09-06 2003-03-20 Alphavax, Inc. Alphavirus replicon vector systems
EP1608762B1 (en) 2003-03-20 2014-01-08 Alphavax, Inc. Improved alphavirus replicons and helper constructs
PT1751289E (pt) 2004-05-18 2009-03-31 Alphavax Inc Vectores de alfavirais derivados da tc-83, partículas e métodos
US20090104226A1 (en) * 2004-05-21 2009-04-23 Novartis Vaccines And Diagnostics Inc. Alphavirus Vectors for Respiratory Pathogen Vaccines
US7332322B2 (en) 2004-09-14 2008-02-19 Ilya Frolov Venezuelan equine encephalitis virus replicons with adaptive mutations in the genome and uses thereof
WO2007098267A2 (en) * 2006-02-27 2007-08-30 The Board Of Regents Of The University Of Texas System Pseudoinfectious flavivirus and uses thereof
EP2049665A2 (en) 2006-07-28 2009-04-22 Applera Corporation Dinucleotide mrna cap analogs
WO2008119827A1 (en) * 2007-04-02 2008-10-09 Fit Biotech Oy Transreplicase constructs
DK2947149T3 (en) 2007-06-21 2018-06-06 Alphavax Inc ALPHAVIRUS REPLICATION PARTICLES FOR USE IN VACCINATION
WO2009058911A2 (en) 2007-10-31 2009-05-07 Applied Biosystems Inc. Preparation and isolation of 5' capped mrna
WO2009079185A2 (en) * 2007-11-26 2009-06-25 Novartis Vaccines And Diagnostics, Inc. Methods of generating alphavirus particles
EP3100718B1 (en) 2008-01-02 2019-11-27 Arbutus Biopharma Corporation Improved compositions and methods for the delivery of nucleic acids
EP2279254B1 (en) 2008-04-15 2017-07-05 Protiva Biotherapeutics Inc. Novel lipid formulations for nucleic acid delivery
CA2724570A1 (en) 2008-05-23 2009-11-26 Kaja Kiiver Expression vector encoding alphavirus replicase and the use thereof as immunological adjuvant
AU2009303345B2 (en) 2008-10-09 2015-08-20 Arbutus Biopharma Corporation Improved amino lipids and methods for the delivery of nucleic acids
WO2010048536A2 (en) 2008-10-23 2010-04-29 Alnylam Pharmaceuticals, Inc. Processes for preparing lipids
EP3699172A3 (en) 2008-11-10 2020-11-18 Arbutus Biopharma Corporation Novel lipids and compositions for the delivery of therapeutics
EP2391343B1 (en) 2009-01-29 2017-03-01 Arbutus Biopharma Corporation Improved lipid formulation for the delivery of nucleic acids
CA3042927C (en) 2009-05-05 2022-05-17 Arbutus Biopharma Corporation Lipid compositions for the delivery of therapeutic agents
KR20220038506A (ko) 2009-06-10 2022-03-28 알닐람 파마슈티칼스 인코포레이티드 향상된 지질 조성물
WO2011082388A2 (en) * 2009-12-31 2011-07-07 Medigen, Inc . Infectious dna vaccines against chikungunya virus
EP4481047A3 (en) 2010-06-03 2025-04-16 Alnylam Pharmaceuticals, Inc. Biodegradable lipids for the delivery of active agents
US10487332B2 (en) * 2010-07-06 2019-11-26 Glaxosmithkline Biologicals Sa Immunisation of large mammals with low doses of RNA
FI4005592T3 (fi) 2010-07-06 2023-01-13 Virionin kaltaisia kuljetuspartikkeleita itsereplikoituville rna-molekyyleille
CA2804591C (en) 2010-07-06 2019-01-22 Novartis Ag Cationic oil-in-water emulsions
CN103153284B (zh) 2010-07-06 2015-11-25 诺华股份有限公司 含有其pKa值有利于RNA递送的脂质的脂质体
US9770463B2 (en) 2010-07-06 2017-09-26 Glaxosmithkline Biologicals Sa Delivery of RNA to different cell types
JP5911870B2 (ja) 2010-08-31 2016-04-27 ノバルティス アーゲー 免疫原をコードするrnaの送達のためのpeg化リポソーム
RS63890B1 (sr) 2010-08-31 2023-02-28 Glaxosmithkline Biologicals Sa Mali lipozomi za isporuku rnk koja kodira imunogen
WO2012170431A2 (en) * 2011-06-06 2012-12-13 Bluebird Bio, Inc. Improved geneswitch systems
US11058762B2 (en) 2011-07-06 2021-07-13 Glaxosmithkline Biologicals Sa Immunogenic compositions and uses thereof
RU2014104090A (ru) 2011-07-06 2015-08-20 Новартис Аг Липосомы с эффективным соотношением n:p для доставки молекул phk
US9636410B2 (en) 2011-07-06 2017-05-02 Glaxosmithkline Biologicals Sa Cationic oil-in-water emulsions
JP2014522842A (ja) 2011-07-06 2014-09-08 ノバルティス アーゲー 免疫原性組み合わせ組成物およびその使用
PT2750707T (pt) 2011-08-31 2019-01-23 Glaxosmithkline Biologicals Sa Lipossomas peguilados para distribuição de arn que codifica imunogénio
US8961995B2 (en) 2012-09-20 2015-02-24 Uab Research Foundation Methods and compositions for alphavirus replicons
WO2014170493A2 (en) 2013-04-19 2014-10-23 Novartis Ag Alphavirus vector
EP3052511A4 (en) 2013-10-02 2017-05-31 Moderna Therapeutics, Inc. Polynucleotide molecules and uses thereof
EP3574923A1 (en) 2013-10-22 2019-12-04 Translate Bio, Inc. Mrna therapy for phenylketonuria
US10842859B2 (en) 2014-03-25 2020-11-24 Yale University Uses of parasite macrophage migration inhibitory factors
EP3061826A1 (en) 2015-02-27 2016-08-31 Novartis AG Flavivirus replicons
DK3294326T3 (da) * 2015-05-15 2021-05-31 Curevac Ag Prime-boost-regimer indbefattende indgivelse af mindst én mrna-konstruktion
DK4276189T3 (da) 2015-09-21 2026-05-26 Trilink Biotechnologies Llc Initierende oligonukleotidprimere med kappe til syntesering af 5'-ende RNA'er med kappe
KR20180074699A (ko) * 2015-11-09 2018-07-03 이뮨 디자인 코포레이션 이종 핵산을 발현하는 rna 레플리콘의 발현 및 투여를 위한 레트로바이러스 벡터
WO2017162266A1 (en) * 2016-03-21 2017-09-28 Biontech Rna Pharmaceuticals Gmbh Rna replicon for versatile and efficient gene expression
EP3471778A4 (en) 2016-06-20 2020-02-19 The Regents of The University of Michigan COMPOSITIONS AND METHOD FOR DELIVERING BIOMACROMOLECOLIC ACTIVE SUBSTANCES
WO2018010815A1 (en) 2016-07-15 2018-01-18 Biontech Rna Pharmaceuticals Gmbh Formulation for administration of rna
ES2993107T3 (en) 2016-10-17 2024-12-23 Janssen Pharmaceuticals Inc Recombinant virus replicon systems and uses thereof
US10487105B2 (en) 2016-10-19 2019-11-26 Arcturus Therapeutics, Inc. Trinucleotide MRNA cap analogs
KR20190093816A (ko) 2016-10-26 2019-08-26 큐어백 아게 지질 나노입자 mRNA 백신
RU2019119272A (ru) * 2016-11-23 2020-12-24 Гритстоун Онколоджи, Инк. Вирусная доставка неоантигенов
JP7788787B2 (ja) 2016-12-05 2025-12-19 ヤンセン ファーマシューティカルズ,インコーポレーテッド 遺伝子発現増強のための組成物および方法
US10383952B2 (en) * 2016-12-21 2019-08-20 Arcturus Therapeutics, Inc. Ionizable cationic lipid for RNA delivery
WO2018119163A1 (en) * 2016-12-21 2018-06-28 Payne Joseph E Ionizable cationic lipid for rna delivery
US20190374650A1 (en) 2017-02-22 2019-12-12 The Regents Of The University Of Michigan Compositions and methods for delivery of polymer/biomacromolecule conjugates
EP3589290A4 (en) 2017-02-28 2020-12-30 Arcturus Therapeutics, Inc. Translatable molecules and synthesis thereof
KR102945203B1 (ko) 2017-05-08 2026-03-31 시애틀 프로젝트 코포레이션 알파바이러스 신생항원 벡터
KR102636537B1 (ko) * 2017-05-31 2024-02-15 울트라제닉스 파마수티컬 인코포레이티드 글리코겐 축적 질환 유형 iii에 대한 치료제
US11015204B2 (en) 2017-05-31 2021-05-25 Arcturus Therapeutics, Inc. Synthesis and structure of high potency RNA therapeutics
WO2019023566A1 (en) * 2017-07-28 2019-01-31 Janssen Vaccines & Prevention B.V. METHODS AND COMPOSITIONS FOR PROVIDING IMMUNIZATION AGAINST Heterologous ARNREP
EP3727444A1 (en) 2017-12-18 2020-10-28 Intervet International B.V. Swine influenza a virus vaccine
KR20200111729A (ko) * 2018-01-19 2020-09-29 얀센 파마슈티칼즈, 인코포레이티드 재조합 레플리콘 시스템을 이용한 면역 반응 유도 및 증진
US12173032B2 (en) 2018-07-13 2024-12-24 The Trustees Of Indiana University Recombinant rotavirus expression system and recombinant rotaviruses
AU2019321186B2 (en) 2018-08-17 2024-05-23 Glaxosmithkline Biologicals Sa Immunogenic compositions and uses thereof
WO2020146700A1 (en) 2019-01-10 2020-07-16 Massachusetts Institute Of Technology Lipid nanoparticles
EP3942050A4 (en) 2019-03-19 2023-02-22 Arcturus Therapeutics, Inc. PROCEDURE FOR THE PRODUCTION OF LIPID-COATED RNA NANOPARTICLES
GB201908729D0 (en) 2019-06-18 2019-07-31 Imp College Innovations Ltd RNA construct
EP3986452A1 (en) 2019-06-18 2022-04-27 CureVac AG Rotavirus mrna vaccine
EP3986458A1 (en) 2019-06-20 2022-04-27 Janssen Sciences Ireland Unlimited Company Self-replicating rna molecules for hepatitis b virus (hbv) vaccines and uses thereof
HRP20241379T1 (hr) 2019-09-30 2024-12-20 Gilead Sciences, Inc. Cjepiva za hbv i postupci za liječenje hbv
WO2021067598A1 (en) * 2019-10-04 2021-04-08 Ultragenyx Pharmaceutical Inc. Methods for improved therapeutic use of recombinant aav
US12194089B2 (en) * 2020-02-04 2025-01-14 CureVac SE Coronavirus vaccine
EP4103228A1 (en) * 2020-02-13 2022-12-21 Institut Pasteur Nucleic acid vaccine against the sars-cov-2 coronavirus
EP4114470A4 (en) * 2020-03-03 2024-04-17 Arcturus Therapeutics, Inc. COMPOSITIONS AND METHODS FOR TREATING ORNITHINE TRANSCARBAMYLASE DEFICIENCY
JP2023517644A (ja) 2020-03-09 2023-04-26 アークトゥラス・セラピューティクス・インコーポレイテッド コロナウイルスワクチン組成物及び方法
EP4376883A4 (en) 2021-07-30 2025-07-16 Arcturus Therapeutics Inc RNA VACCINES

Similar Documents

Publication Publication Date Title
US12397048B2 (en) Bunyavirales vaccine
Fang et al. Advances in COVID-19 mRNA vaccine development
US12350330B2 (en) RSV RNA molecules and compositions for vaccination
Lundstrom Replicon RNA viral vectors as vaccines
JP2018186815A5 (cg-RX-API-DMAC7.html)
JP2023551982A5 (cg-RX-API-DMAC7.html)
Collins et al. Viral vectors in cancer immunotherapy: which vector for which strategy?
US20200405844A1 (en) Combination hpiv3/hmpv rna vaccines
JP2004501646A5 (cg-RX-API-DMAC7.html)
JP2021512123A5 (cg-RX-API-DMAC7.html)
JP2010530245A5 (cg-RX-API-DMAC7.html)
JP2023523414A5 (cg-RX-API-DMAC7.html)
ES2585735T3 (es) Nuevas proteínas de fusión y su aplicación para la preparación de vacunas contra la hepatitis C
JP2020510426A5 (cg-RX-API-DMAC7.html)
WO2008007581A1 (en) Non-replicating paramyxoviridae virus vector
FI4305181T3 (fi) Minimaalinen nefriinipromoottori
CN106459997A (zh) 用于疫苗应用的高效价病毒样囊泡的进化
JP2023523413A5 (cg-RX-API-DMAC7.html)
CN118556131A (zh) 用于蛋白质表达的mRNA及其模板
Lundstrom Semliki Forest virus vectors for gene therapy
Lundstrom Self-replicating RNA viral vectors in vaccine development and gene therapy
JP2021507707A5 (cg-RX-API-DMAC7.html)
Lundstrom Application of viruses for gene therapy and vaccine development
Lundstrom Latest trends in cancer therapy applying viral vectors
Von Messling et al. Toward novel vaccines and therapies based on negative-strand RNA viruses